Clearmind announces publication of international patent application

Clearmind Medicine announced the publication of an international patent application under the Patent Cooperation Treaty for its combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines. The patent application was filed as part of the Company’s ongoing collaboration with SciSparc. Under this collaboration, the two companies are researching combination therapies that integrate psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.